Abstract：
Breast cancer represents the most commonly diagnosed neoplasm worldwide and the HER2-positive subtype accounts for nearly 1 in 5 breast cancers. The majority of patients with breast cancer present with an early-stage disease upon diagnosis, which is thus susceptible to virtually curative treatment strategies. For a stage, I T1a/b N0 HER2-positive disease, upfront surgery followed by adjuvant therapy is the preferred approach. However, there is some uncertainty regarding the appropriate management of stage cT1c cN0, as both the neoadjuvant approach and upfront surgery have been proven to be feasible therapeutic options. The aim of this Delphi consensus was to define the best strategies for the treatment of early HER2-positive breast cancer. This work may help clinicians in the management of early HER2-positive breast cancer.
摘要：
乳腺癌是世界上最常见的诊断肿瘤，HER2阳性亚型占乳腺癌的近1/5。大多数乳腺癌患者在诊断后出现早期疾病，因此容易受到几乎治愈性治疗策略的影响。对于一个舞台，IT1a/bN0HER2阳性疾病，前期手术后辅助治疗是首选方法.然而,cT1ccN0期的适当管理存在一定的不确定性,因为新辅助方法和前期手术均已被证明是可行的治疗选择.本德尔菲共识的目的是确定治疗早期HER2阳性乳腺癌的最佳策略。这项工作可能有助于临床医生管理早期HER2阳性乳腺癌。
